The price of Upadacitinib varies by region, dosage specification, and purchasing channel. In domestic public hospitals or formal pharmacies, it is generally priced at 600–1500 RMB per box (taking 15 mg × 30 tablets per box as an example). As a prescription drug, it must be used strictly under medical supervision and cannot be purchased or dose-adjusted without a doctor’s guidance.
Factors Affecting Price
Dosage specifications: Prices differ for different strengths (e.g., 5 mg, 15 mg) or quantities (e.g., 14 tablets, 30 tablets).
Medical insurance policy: Upadacitinib may be covered by medical insurance in some regions, reducing out-of-pocket expenses. Consult local hospitals or insurance authorities for details.
Purchasing channels: Prices may vary among public hospitals, chain pharmacies, and authorized online platforms. Purchase only through legitimate and formal channels.
Precautions for Use
Indications
It is mainly indicated for moderate to severe rheumatoid arthritis, psoriatic arthritis, and other immune-mediated diseases. A prescription requires evaluation by a physician.
Contraindications and Side Effects
It may increase the risk of infections, thrombosis, or abnormal liver function. Regular follow-ups are required during treatment; seek medical attention promptly if adverse reactions occur.
Special Populations
Use with caution in pregnant women, breastfeeding women, and patients with hepatitis or tuberculosis.
Medical Guidance
If you need to use Upadacitinib:
Consult a doctor in the Department of Rheumatology and Immunology or Dermatology for condition and treatment evaluation.
Avoid live vaccines during treatment and inform your doctor of all other medications you are taking.
For long-term users, recheck blood routine, liver and kidney function, and other indicators every 3–6 months.
As drug prices may change with policy adjustments or market fluctuations, obtain the latest information through hospital pharmacies, official cooperative platforms, etc., and strictly follow the prescribed treatment regimen.
